MNPR (Monopar Therapeutics) ROCE %: -15.28% (As of Mar. 2026)


MNPR Monopar Therapeutics Inc MNPR
35 GF Score
Price $89.10
! 2 Warning Signs
View Full Analysis

What is Monopar Therapeutics ROCE %?

Monopar Therapeutics MNPR +9.14% 35 ROCE % is -15.28% as of Mar. 2026. GuruFocus rates MNPR with a GF Score™ of 35/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Monopar Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -15.28%.

Monopar Therapeutics  (NAS:MNPR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Monopar Therapeutics ROCE % Related Terms

Monopar Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Monopar Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monopar Therapeutics ROCE % Chart

Monopar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -52.71 -72.57 -112.60 -53.32 -17.31

Monopar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.73 -24.44 -16.89 -17.61 -15.28
MNPR
35GF Score
Monopar Therapeutics Inc MNPR
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monopar Therapeutics ROCE % Calculation

Monopar Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-16.704/( ( (60.291 - 5.254) + (140.718 - 2.735) )/ 2 )
=-16.704/( (55.037+137.983)/ 2 )
=-16.704/96.51
=-17.31 %

Monopar Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-20.9/( ( (140.718 - 2.735) + (137.984 - 2.458) )/ 2 )
=-20.9/( ( 137.983 + 135.526 )/ 2 )
=-20.9/136.7545
=-15.28 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -15.28% mean?
Monopar Therapeutics (MNPR) has a ROCE % of -15.28% as of Mar. 2026.
Is Monopar Therapeutics' ROCE % too high?
Monopar Therapeutics' current ROCE % is -15.28%. Overall, Monopar Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' ROCE % compare to IPSC and ADCT?
Monopar Therapeutics' ROCE % of -15.28% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Monopar Therapeutics's current ROCE % is -15.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current ROCE % of -15.28%. The current ROCE % is -15.28%. Monopar Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current ROCE % is -15.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monopar Therapeutics Business Description

Address 1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
35GF Score

Get the complete analysis for MNPR

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$89.10
Price